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Understanding Infections Caused 




Infectious diseases caused by virus, bacteria and fungi represent a major  
apprehension globally in terms of detrimental public health and economy. Some of 
the infectious agents such as virus (e.g., Coronavirus, influenza, Ebola, chicken-
pox), bacteria (e.g., tuberculosis, cholera, whooping cough) are highly contagious 
and are responsible for communicable diseases. Communicable diseases spread 
from person to person through close contact including touching and kissing, also 
via coughing and sneezing, contamination of food and water. Many bacteria are 
also opportunistic pathogens and are commonly cause mild–moderate infections 
including sore throat, acne, tooth decay, urinary tract infections, cellulitis/skin 
infection, sexually transmitted infection, bacterial vaginosis, peptic/stomach ulcer, 
keratitis/eye infection, to severe/life-threatening infections such as pneumoniae, 
septicaemia/sepsis, meningitides in humans, animals, and birds. Most opportu-
nistic bacteria exist as a commensal flora within the host body (gastrointestinal 
tract, skin, mucosal, oral, and nasal cavity, urogenital tract) and commonly found 
in abiotic surfaces (water, food, soil) in the environment [1, 2]. Under normal 
conditions i.e., in healthy people these bacterial pathogens do not cause infections. 
Infections caused by opportunistic bacteria are primarily triggered by either inva-
sion of host commensal bacteria or bacteria from environmental sources gets into 
host bodily tissue [1, 2]. However, these opportunistic bacteria primarily target and 
cause fatal infections in immunocompromised people including acquired immu-
nodeficiency syndrome (AIDS/HIV positive) patients, cancer patients (treated 
with immunosuppressive drugs, corticosteroids), hospital admitted patients for 
surgery, patients with underlying diseases such as cystic fibrosis, diabetes [2]. 
Most common examples of opportunistic bacteria found in mammals, birds and 
environment are Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus 
epidermidis, Escherichia coli, Klebsiella pneumoniae, Neisseria meningitides, 
Acinetobacter baumannii, Helicobacter pylori, Streptococcus pneumoniae, Streptococcus 
pyogenes, Streptococcus mutans, Clostridioides difficile, Legionella pneumophila, 
Propionibacterium acnes, etc. On the other hand, mammalian and bird’s body also 
host different species of good bacterial species (probiotics) which are essential for 
general wellbeing [3]. Lactobacillus and Bifidobacteria species are the common 
example of probiotics bacteria that are present in the mammalian digestive tract, 
they aid in maintaining daily healthy lifestyle includes food digestion, balancing pH 
of the body, alleviate symptoms of Gastroesophageal reflux diseases (GERD) such 
as heartburn, acid-reflux [4, 5].
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2.  Biofilms associated infection and its impact on human health and 
economy
Infection is predominantly triggered by biofilm formation. It is projected that 
more than 60% of all bacterial infections are associated with biofilms [6]. In simple 
words, biofilms mean colonization of bacteria on biotic and abiotic surfaces. 
Biofilm is the most supreme stage of bacterial lifestyle. Biofilm formation involves 
various stages to instigate with initial adhesion (reversible adhesion) of individual 
bacteria (planktonic stage) through their cell appendages (flagella, fimbriae, pili, 
that are anchored to bacterial cell surface) to host bodily surfaces such as skin, 
mucosa, and teeth also on medical devices such as implants, catheters, contact 
lenses and on water pipes, sinks, bathtub. The second steps are microcolony 
formation and biosynthesize of numerous exogenous biopolymers by bacteria such 
as nucleic acids (extracellular DNA, RNA), proteins, polysaccharides, virulence 
factors and metabolites that aids them in irreversible/strong adhesion to the sur-
faces, cell-to-cell adhesion, and foundation for initial architecture for biofilm. Later 
stages include further maturation and growth of bacteria within the microcolony 
and production of biomolecules and formation of robust three-dimensional biofilm 
and finally dispersion of individual bacteria from the mature biofilms to initiate 
colonization at new site [7, 8]. This close vicinity of the bacterial cells within the 
biofilm empowers exchange and distribution of various essential products includes 
nutrients, genetic materials, proteins, metabolites and other small molecules for the 
fitness, growth, and survival of bacterial cells and exclusion of toxic end products 
[9]. The complex biofilm architecture defends the bacterial cells within them from 
antibiotics, antiseptics, soaps and detergents, physical shear forces and the host 
immune system [10].
The prevalence and persistence of biofilm associated infections has direct 
adverse impact on human health and World’s economy including costing billions 
of dollars annually for treatment across several different sectors such as wound 
and burns treatment, dentistry, endocarditis, bronchitis’s, cystic fibrosis and 
surgical (hip, knee joints, pacemakers, cardiac valves) and non-surgical (contact 
lenses, urinary catheters, artificial teeth) implants [11, 12]. For instance, United 
States of America spends approximately 94 billion USD a year with more than 
half a million deaths related to biofilms [13]. Biofilm related Hospital-acquired 
infections/nosocomial infection includes pneumoniae, surgical site infections, 
Urinary tract infections (UTIs), blood stream infections alone cost USA health care 
11 billion USD with approximately 2 million cases per year and is responsible for 
fourth leading cause of deaths in USA [6, 14, 15]. In general, it is speculated that 
nosocomial infection in patients becomes apparent within 48 hrs of early patient 
care [14]. Australia’s health system already expended $909 million annually for 
treatment associated with Urinary tract infections (UTIs). To note: the ratio of 
patients affected with UTIs in Australia is estimated to be 1 out of 2 women and 
1 out of 20 men in their lifetime. UTIs associated implications in Australia also 
resulted in over 2.5 million visits to clinics and 75,000 hospital stay yearly [16]. 
As per statistics, report by European centre for disease prevention and control, 
nosocomial infection rate in European Union countries is soar, estimated to be 
around 3 million people get infected and around 50,000 death associated with it per 
year [17]. Primary factors that trigger the increase in infection rate, morbidity and 
mortality and associated treatment cost are due to poor hygiene, malnutrition, and 
lack of sanitation especially in the low-income countries, also misuse of antibiotic 
in food industry (agriculture, livestock, dairy) and unwarranted prescription (e.g., 
antibiotics prescribed to patients for common cold). Development of multidrug 
resistance bacteria or superbugs further escalates infection rate and associated 
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treatment cost and death rate. News article published by leading newspaper “Times 
of India” reported mortality rate in India due to superbugs is 13% in comparison to 
2–7% in developed countries [18]. Biofilms also posses’ serious threat to food sector 
including agriculture, dairy, and livestock. It is estimated that infections in plants 
by microbial biofilms add to 10% of global food supply loss and directly contribute 
to foodborne infections [11]. Bovine mastitis, potentially fatal mammary gland 
infection/inflammation of the udder in cow, caused by bacteria attribute to loss of 
two billion dollars to the US dairy industry [11].
3. Pseudomonas aeruginosa a critical opportunistic bacterium
Pseudomonas aeruginosa, is one such opportunistic Gram-negative rod-shaped 
bacterial pathogen known for its ubiquity. World health organization (WHO) 
have placed P. aeruginosa in top priority (critical) organism list considering its 
intrinsic antibiotic resistance profile and remarkable ability to acquire tolerance 
to antibacterial agents [19]. In addition, P. aeruginosa forms robust biofilm and 
triggers severe infections especially in immunocompromised and hospital admitted 
patients. P. aeruginosa commonly found in human gastrointestinal tract, skin, soil, 
water, meat, plants, and vegetables and one of the leading causes for blood stream 
infection, UTI, microbial keratitis, wound and burn infection, HIV/AIDS patients, 
in ICU patients (ventilator associated pneumoniae) and a leading death cause in 
cystic fibrosis patients. P. aeruginosa associated hospital-acquired infections ranges 
between 10 and 15% globally [20]. Global epidemiology survey on P. aeruginosa, 
recorded numerous antibiotic resistance strains isolated from infected patients. 
These isolates are resistance to many antibiotics (carbapenem, gentamicin, cipro-
floxacin, tobramycin, meropenem, and others) which are commonly used to treat 
infected patients [21–24]. This bacterium secretes numerous biomolecules such 
as DNA, proteins, polysaccharides, pyocyanin, rhamnolipids, siderophores which 
supports them in colonization at infection site and spread virulence in host and 
shield them from antibacterial agents [25]. In this book, we elaborated on general 
bacterial biofilm and in specifically focused on mechanism of P. aeruginosa biofilm 
formation, pathogenicity, antibiotic resistance, and treatment. The collections of 
chapters in this book will enlighten different end users including infectious diseases 
scientist, medical professional, medical and microbiology students and public.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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